Uncovering Coenzyme Q10-Related Genetic Determinants of Statin-Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

Genetic variants in CoQ10 biosynthesis genes — association with statin-induced muscle symptom risk

Genetic variants in CoQ10 biosynthesis pathway genes are identified as predictors of statin-associated muscle symptoms (SAMS) in UK Biobank and the All of Us Research Program. SAMS represent the leading cause of premature statin discontinuation. These findings provide mechanistic insights into the statin–mitochondrial metabolism link and may yield genetic biomarkers for SAMS risk prediction. ⚠️ Summary written from title (RSS abstract unavailable — authors/PMID to verify via DOI).

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The CoQ10 pathway is a biologically plausible mechanism for SAMS — statins inhibit HMG-CoA reductase, an enzyme shared by cholesterol and CoQ10 biosynthesis. Identifying genetic variants in this pathway as SAMS risk predictors opens the door to specific PGx genotyping to personalize statin prescribing — a real clinical need given the frequency of SAMS.

Clinical impact : 2/3 · Evidence strength : 2/3 · Novelty : 2/2 · Sample size : 1/1 · Journal quality : 1/1 → Total : 8/10